Biopsies were selected to represent all breast cancer subtypes (Sorlie et al. 2001), with a focus on the aggressive triple-negative tumors (N = 66 triple-negative; 22 Luminal A; 22 Luminal B; 34 ERBB2 [also known as HER2] positive). This evidence concerns the gene ERBB2 and breast cancer.